As Entresto Sales Soar, Novartis Braces For Generics Battle
Swiss Major Is Banking On China To Drive Growth
Novartis CEO Vas Narasimhan has told Scrip that the company is “aggressively defending each group of patents” on its cardiovascular blockbuster which topped the $900m sales mark in the fourth quarter.
